| Deborah M O Hara, PA C | |
|
63 Crescent Ave, Green Mountain Family Practice, Northfield, VT 05663-5704 | |
| (802) 485-4161 | |
| (802) 485-4163 |
| Full Name | Deborah M O Hara |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 63 Crescent Ave, Northfield, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932182292 | NPI | - | NPPES |
| 90002631 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 0550030353 (Vermont) | Secondary |
| 363A00000X | Physician Assistant | 055.0030933 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Deborah M O Hara, PA C Po Box 547, Central Vermont Medical Center - Finance Dept, Barre, VT 05641-0547 Ph: (802) 485-4161 | Deborah M O Hara, PA C 63 Crescent Ave, Green Mountain Family Practice, Northfield, VT 05663-5704 Ph: (802) 485-4161 |
News Archive
As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial. The lead investor in the company, MIG-Fonds, is extremely satisfied with the expanding patent portfolio of Affiris GmbH.
For seven straight years since turning 40, Amy Colton religiously scheduled a mammogram. Every year, the test showed nothing. Two years ago, however, the registered nurse was shocked to discover she was in the latter stages of breast cancer. ... Now she's even more shocked that California's powerful medical lobby is trying to block legislation that would require physicians to tell women if they have the condition, known as "extremely dense breast tissue."
GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.
CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).
A signaling pathway controlled by transforming growth factor beta (TGF-beta) could be involved in the progression of age-related macular degeneration.
› Verified 4 days ago